Beauty Farm Med & Health Ind (2373) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Beauty Farm Med & Health Ind stock HK$37.50, price HK$18.28, upside +105.1%, quality 62 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
46‑month range HK$8.99 – HK$38.52 · fair‑value band HK$26.25 – HK$48.75 · the HK$18.28 price screens below the HK$37.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Beauty Farm Med & Health Ind in your weekly email
Every Wednesday you see whether Beauty Farm Med & Health Ind is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Beauty Farm Medical and Health Industry Inc. provides beauty and health management services in the People's Republic of China. It offers traditional beauty, aesthetic medical, subhealth assessment; and intervention services.
Show moreShow less
The company markets its products under the Beauty Farm, Palaispa, Neology, and CellCare brand names. The company was founded in 1993 and is headquartered in Shanghai, the People's Republic of China.
Stock analysis
Beauty Farm Med & Health Ind (2373) currently trades at HK$18.28, while our model-based Fair Value estimate is HK$37.50, implying the stock looks roughly 51% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$68.17 per share, and 19 of the 24 models we run sit above the HK$18.28 price.
Bear case: the Dividend Discount group reads lowest at HK$6.44, and 5 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: HK$26.25 (bear) to HK$48.75 (bull), the price of HK$18.28 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Beauty Farm Med & Health Ind reported revenue of 3.0B CNY in FY2025 versus 1.8B CNY in FY2021, a compound +13.9%/yr. Reported net income was 318M CNY in FY2025, compounding +13.2%/yr from FY2021.
Key figures
Market cap HK$4.5B (≈ $572M) Small · P/E ratio 9.2 · P/S ratio 0.98 · Dividend yield 3.4% · Net margin 10.6% · Return on equity 34.1% · Return on assets (EBIT) 8.6% (5-year average) · Operating margin 17.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (medium confidence).
What moves the price
The share trades about 39% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 105%, 2373 screens cheaper than that median.
Fair Value models
BearHK$26.25Fair Value HK$37.50BullHK$48.75
Price HK$18.28 · Upside +105.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+19.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+15.9%
Dividend (yield on the price)3.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 15%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−28.3%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −29.4% a year for the price and +12.3% for the forecasts.
Compare Beauty Farm Med & Health Ind with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+105.1% · Top 25%
Profitability
Return on equity (12 months)34.1% · Top 25%
Return on assets6.3% · Above median
Net margin (12 months)11.2% · Above median
Operating margin (12 months)17.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)29.0% · Top 25%
Dividend yield (12 months)3.4% · Above median
Balance sheet
Debt / equity0.63× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)9.2× · Cheapest 25%
P/B3.73× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Beauty Farm Med & Health Ind Fair Value". https://www.fairvalue-calculator.com/stock/2373
Frequently asked questions
Is Beauty Farm Med & Health Ind (2373) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of HK$37.50 versus a price of HK$18.28, about +105% upside (undervalued).
What is the fair value of 2373?
Our model-based fair value for Beauty Farm Med & Health Ind is HK$37.50 (as of Nov 7, 2026), built from audited fundamentals. The current price: HK$18.28.
What is the quality score of 2373?
Beauty Farm Med & Health Ind has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beauty Farm Med & Health Ind (2373)?
Our model-based price target is the fair value of HK$37.50 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario HK$26.25, optimistic scenario HK$48.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Beauty Farm Med & Health Ind stock forecast for 2026?
Our models put fair value at HK$37.50, about +105% upside versus a price of HK$18.28 (undervalued). Cautious scenario HK$26.25, optimistic scenario HK$48.75. The calculation is refreshed regularly with new filings.
What is the revenue of Beauty Farm Med & Health Ind (2373)?
Beauty Farm Med & Health Ind reported trailing-twelve-month revenue of about 3.4B CNY (latest available figure, as of Nov 7, 2026).
Does Beauty Farm Med & Health Ind pay a dividend?
Beauty Farm Med & Health Ind currently shows a dividend yield of 3.45% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Beauty Farm Med & Health Ind (2373) and when is the ex-dividend date?
Beauty Farm Med & Health Ind pays a dividend of HK$0.63 per share a year, a dividend yield of 3.4%. The last ex-dividend date was Aug 19, 2026. The payout ratio is 41.8% of earnings. Free cash flow covers the dividend 7.02 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Beauty Farm Med & Health Ind (2373)?
For today's price to be fair in a discounted-cash-flow model, Beauty Farm Med & Health Ind would have to grow free cash flow by -28.3 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.8 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 2373 use?
Our models discount Beauty Farm Med & Health Ind at 12.7 %: a base by market capitalisation (small), damped by beta 1.32, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Beauty Farm Med & Health Ind that is -28.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has Beauty Farm Med & Health Ind (2373) delivered so far?
Over the past 5 years revenue at Beauty Farm Med & Health Ind grew +14.8 % a year. The price currently implies free-cash-flow growth of -28.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Beauty Farm Med & Health Ind (2373) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Beauty Farm Med & Health Ind (-28.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Beauty Farm Med & Health Ind (2373)?
The free-cash-flow yield on the price is 24.43 %: that much free cash flow Beauty Farm Med & Health Ind produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Beauty Farm Med & Health Ind (2373)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beauty Farm Med & Health Ind it is HK$37.50 per share (as of Nov 7, 2026), against a price of HK$18.28. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Beauty Farm Med & Health Ind stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 2373 trades below its calculated fair value: price HK$18.28, fair value HK$37.50, a gap of about +105% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2373?
No. The price is what the market pays today (HK$18.28); the fair value is what the company's own numbers justify (HK$37.50). For Beauty Farm Med & Health Ind the two are HK$19.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beauty Farm Med & Health Ind worth?
The market values Beauty Farm Med & Health Ind at about HK$4.5B (market capitalisation, as of Nov 7, 2026). Per share that is HK$18.28; our models calculate a fair value of HK$37.50 per share.
What do the bullish and bearish scenarios say about 2373?
Our models span a range for Beauty Farm Med & Health Ind: cautious scenario HK$26.25, base HK$37.50, optimistic HK$48.75 per share (as of Nov 7, 2026, price HK$18.28). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2373?
Beauty Farm Med & Health Ind trades at a price-to-earnings ratio of 9.2 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$37.50 is built from several models across several years. Other multiples: P/B 3.7, P/S 1.1, EV/EBITDA 4.4.
How solid is the balance sheet of Beauty Farm Med & Health Ind (2373)?
Balance-sheet figures for Beauty Farm Med & Health Ind (as of Nov 7, 2026): return on equity 34.1%, debt of 0.63 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 2373 from its 52-week high?
Beauty Farm Med & Health Ind trades at HK$18.28, about 39% below its 52-week high of HK$29.98 and 15% above the low of HK$15.94 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$37.50 is for.
Which stocks are comparable to Beauty Farm Med & Health Ind?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beauty Farm Med & Health Ind stock attractive at the current price?
The data as of Nov 7, 2026: price HK$18.28, calculated fair value HK$37.50 (+105%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2373 calculated?
We run Beauty Farm Med & Health Ind through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$37.50 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Beauty Farm Med & Health Ind currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beauty Farm Med & Health Ind (2373)?
The closing price on Nov 6, 2026 was HK$18.28. Our model-based fair value is HK$37.50, about +105% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beauty Farm Med & Health Ind right now?
The price is below even our cautious bear case (HK$26.25). The market is more pessimistic than our downside scenario. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$26.25 to HK$48.75) leaves room in how you read the outcome.
Key figures of Beauty Farm Med & Health Ind
How large is the market capitalisation of Beauty Farm Med & Health Ind (2373)?
The market capitalisation of Beauty Farm Med & Health Ind is HK$4.5B (≈ $572M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beauty Farm Med & Health Ind (2373)?
The price-to-sales ratio of Beauty Farm Med & Health Ind is 0.98 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Beauty Farm Med & Health Ind (2373)?
The dividend yield of Beauty Farm Med & Health Ind is 3.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beauty Farm Med & Health Ind (2373)?
The net margin of Beauty Farm Med & Health Ind is 10.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beauty Farm Med & Health Ind (2373)?
The return on equity (ROE) of Beauty Farm Med & Health Ind is 34.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beauty Farm Med & Health Ind (2373)?
On an EBIT basis the return on assets of Beauty Farm Med & Health Ind is 8.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beauty Farm Med & Health Ind (2373)?
The operating margin of Beauty Farm Med & Health Ind is 17.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beauty Farm Med & Health Ind (2373)?
Revenue at Beauty Farm Med & Health Ind is growing +29.0% versus a year earlier (3y avg +22.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beauty Farm Med & Health Ind (2373)?
Earnings per share at Beauty Farm Med & Health Ind are growing +34.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Beauty Farm Med & Health Ind (2373) carry?
The net debt of Beauty Farm Med & Health Ind is 156M CNY (fiscal year 2025, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Beauty Farm Med & Health Ind in the live analysis
One click puts Beauty Farm Med & Health Ind on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026